抑制非洲疟疾的经济方面
1Blue Nile Associates, 25558 Road N.6, Cortez, Colorado 81321, USA.
MalariaWorld journal
|May 20, 2024
概括
投资抑制疟疾为非洲国家带来了显著的经济效益,投资回报率为3.4比1. 这表明自我资助的疟疾控制可能是这些国家的可持续战略.
科学领域:
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
- 流行病学 流行病学
背景情况:
- 疟疾抑制策略,特别是世界卫生组织 (WHO) 的策略,依赖于国际资金,成本不断上升.
- 到2010年,国际捐助者的疲劳迫使非洲国家需要探索可持续的,自筹资金的疟疾控制.
- 非洲国家可能需要实施永久性疟疾抑制方法,以避免经济限制.
研究的目的:
- 评估非洲国家对疟疾抑制投资的经济效益.
- 确定疟疾抑制是否为受益国家带来积极的投资回报.
主要方法:
- 采用了两个并行流行病学分析:前后比较和治疗和未治疗国家的同时比较.
- 利用了从2007年到2012年参与美国总统非洲疟疾倡议 (PMI) 的国家的数据.
主要成果:
- 与未接受PMI治疗的国家相比,接受PMI治疗的国家的人口和GDP的相对增长更大.
- 在14个接受治疗的国家中,抑制疟疾导致五年内GDP增加约477亿美元.
- 对抗疟疾的投资带来了3.4比1的回报,而2012年之后的成本急剧上升.
结论:
- 抑制疟疾可以在经济上有利于非洲国家独立进行.
- 目前的疟疾抑制方法 (杀菌剂和药物) 的长期可行性是持续获益的关键因素.
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


